Clinical Trial Update: The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating topiramate for prophylaxis in patients with sudden sensorineural hearing loss is ongoing, with the status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sudden Deafness
• Sudden Sensorineural Hearing Loss

Drugs mentioned

• Topiramate (Topiramate)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Sudden Deafness, Sudden Sensorineural Hearing Loss | Phase 2 | Status: UNKNOWN